UBS Group’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,734
| Closed | -$612 | – | 10651 |
|
|
2024
Q4 | $612 | Buy |
3,734
+3,068
| +461% | +$518 | ﹤0.01% | 9409 |
|
|
2024
Q3 | $90 | Sell |
666
-3,995
| -86% | -$644 | ﹤0.01% | 9170 |
|
|
2024
Q2 | $1.26K | Buy |
4,661
+2,279
| +96% | +$935 | ﹤0.01% | 8610 |
|
|
2024
Q1 | $1.5K | Buy |
+2,382
| New | +$2.19K | ﹤0.01% | 8121 |
|
|
2023
Q2 | – | Sell |
-1,670
| Closed | -$1.67K | – | 9532 |
|
|
2023
Q1 | $1.67K | Buy |
+1,670
| New | +$1.67K | ﹤0.01% | 8678 |
|
|
2022
Q4 | – | Sell |
-6,901
| Closed | -$1K | – | 11077 |
|
|
2022
Q3 | $1K | Buy |
6,901
+6,470
| +1,501% | +$1.41K | ﹤0.01% | 10020 |
|
|
2022
Q2 | $0 | Buy |
+431
| New | +$87 | ﹤0.01% | 10845 |
|
|
2021
Q4 | – | Sell |
-234
| Closed | – | – | 10639 |
|
|
2021
Q3 | $0 | Buy |
234
+64
| +38% | +$27 | ﹤0.01% | 10001 |
|
|
2021
Q2 | $0 | Sell |
170
-12,287
| -99% | -$5.53K | ﹤0.01% | 9754 |
|
|
2021
Q1 | $6K | Buy |
12,457
+11,393
| +1,071% | +$7.34K | ﹤0.01% | 8250 |
|
|
2020
Q4 | $1K | Sell |
1,064
-11,305
| -91% | -$6.2K | ﹤0.01% | 8245 |
|
|
2020
Q3 | $6K | Buy |
12,369
+5,870
| +90% | +$2.62K | ﹤0.01% | 7231 |
|
|
2020
Q2 | $3K | Buy |
+6,499
| New | +$1.52K | ﹤0.01% | 7556 |
|
Other funds holding RVPHW
UBS Group's RVPHW Position: Q1 2025 in Review
UBS Group sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q1 2025, closing a stake of 3,734 shares — an estimated $612 sold.
UBS Group first reported a position in RVPHW in Q2 2020 and held it in 13 quarters. The position peaked at $6K in Q1 2021. 1 fund tracked by Wall St. Rank holds RVPHW as of Q1 2025.
- UBS Group reported no remaining Reviva Pharmaceuticals Warrants position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 3,734 Reviva Pharmaceuticals Warrants shares in Q1 2025, an estimated $612.
- UBS Group first reported a position in Reviva Pharmaceuticals Warrants in Q2 2020 and held it in 13 quarters.
- UBS Group's Reviva Pharmaceuticals Warrants position peaked at $6K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.